Τίτλος:
Receptor-Binding Cancer Antigen expressed on SiSo cells (RCAS1)
expression in human benign and malignant thyroid lesions
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Background: The receptor-binding cancer antigen expressed on SiSo cells
(RCAS1) is a human tumor-associated antigen that contributes to tumor
progression by enabling cancer cells to evade immune surveillance. The
present study aimed to evaluate the clinical significance of RCAS1
expression in human benign and malignant thyroid lesions.
Material/Methods: RCAS1 protein expression was assessed
immunohistochemically on paraffin-embedded thyroid tissues from 121
patients with benign and malignant lesions and was associated with type
of thyroid histopathology and tumor stage parameters such as tumor size,
lymph node metastases, capsular, lymphatic and vascular invasion.
Results: RCAS1 positivity, overexpression and staining intensity
provided a distinct discrimination between benign and malignant thyroid
cases (p=0.0006, p=0.0001 and p=0.0001, respectively), as well as
between hyperplastic nodule and papillary carcinoma cases (p=0.0229,
p=0.0001 and p=0.0001, respectively). RCAS1 positivity, overexpression
and staining intensity also provided distinct discrimination between
cases with Hashimoto thyroiditis and those with hyperplastic nodule
(p=0.0221, p=0.0001 and p=0.0019, respectively). In the subgroup of
malignant thyroid lesions, RCAS1 overexpression was significantly
associated with large tumor size (p=0.0246), the presence of lymph node
metastases (p=0.0351) and capsular invasion (p=0.0397).
Conclusions: RCAS1 protein may participate in thyroid neoplastic
transformation and could be considered as a useful biomarker to improve
diagnostic scrutiny.
Συγγραφείς:
Giaginis, Constantinos
Demetriou, Nikoleta
Alexandrou, Paraskevi
and Stolakis, Vasileios
Delladetsima, Ioanna
Klijanienko, Jerzy
and Griniatsos, Ioannis
Theocharis, Stamatios
Περιοδικό:
Medical science monitor basic research
Εκδότης:
International Scientific Literature Inc
Λέξεις-κλειδιά:
RCAS1; thyroid malignancy; immunohistochemistry; clinicopathological
parameters; diagnosis; biomarker
